Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[11C]CPPC PET Imaging in ALS
NCT04749433Phase 1Terminated
- Sponsor
- Johns Hopkins University
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 11C-CPPC in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Safety of use of [11C]CPPC in patients with ALS as assessed by adverse events at 10 days, Safety of use of [11C]CPPC in patients with ALS as assessed by a change in neurological status at 10 days and 2 more. Started Sep 2021; status: terminated.
02
Drugs
11C-CPPC
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04749433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04749433.